Google
Trusted Resources: News & Events
Latest announcements and gatherings
BCL11A-based gene therapy for sickle cell disease passes key preclinical test
A precision-engineered gene therapy virus, inserted into blood stem cells that are then transplanted, markedly reduced sickle-induced red-cell damage in mice with sickle cell disease, researchers from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center report today in the Journal of Clinical Investigation.
The work sets the stage for bringing a decades-old discovery about sickle-cell disease to the bedside. A clinical gene therapy trial, using a virus rendered harmless in the laboratory, is expected to launch in the coming year.
+myBinderRelated Content
-
Novo Nordisk obtains licence for sickle cell disease programNovo Nordisk inked a global licence deal...
-
CRISPR could end sickle cell disease, but signing up black patients for clinical trials will be a hard sellThe first attempts to use a groundbreaki...
-
UH BEATS programhttps://www.youtube.com/watch?v=lzvl_tyv...
-
Siklos®, the first and only hydroxyurea-based treatment for pediatric patients with sickle cell anemia, now availab...Medunik USA, a company dedicated to impr...
-
Discovery could help treatments for sickle cell diseaseResearch team establishes biomarkers for...
-
New treatment plan leads to better pain control for acute sickle cell crisisThere’s new hope for the 70,000 to 80,...
-
Splenectomy to optimize hemoglobin s control in children with sickle cell disease on chronic transfusion therapy for...Background: Consensus guidelines recomme...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.